This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

lixisenatide (Lyxumia®)

Reference No. 863

Publication date:

Last review date:

Appraisal information

lixisenatide (Lyxumia®) 10 micrograms solution for injection
lixisenatide (Lyxumia®) 20 micrograms solution for injection

Company: Sanofi-Aventis Ltd
BNF category: Endocrine system
NMG meeting date: 23/10/2013
AWMSG meeting date: 20/11/2013
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3113
Ratification by Welsh Government: 06/12/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

Lixisenatide (Lyxumia®) is recommended as an option for restricted use within NHS Wales. Lixisenatide (Lyxumia®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control: • In combination with basal insulin, with or without oral glucose-lowering medicinal products, in patients uncontrolled on basal insulin; • In combination with oral glucose-lowering medicinal products in patients uncontrolled on two or more oral glucose-lowering medicinal products. Lixisenatide (Lyxumia®) is not recommended for use within NHS Wales outside of these circumstances.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary